Cargando…

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

INTRODUCTION: Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but resistance develops. This study assessed the maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activity of ceritinib, a novel ALK inhibitor (ALKi), in J...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishio, Makoto, Murakami, Haruyasu, Horiike, Atsushi, Takahashi, Toshiaki, Hirai, Fumihiko, Suenaga, Naoko, Tajima, Takeshi, Tokushige, Kota, Ishii, Masami, Boral, Anthony, Robson, Matthew, Seto, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467585/ https://www.ncbi.nlm.nih.gov/pubmed/26020125 http://dx.doi.org/10.1097/JTO.0000000000000566

Ejemplares similares

Significant Radiologic Response of Pancreatic Metastasis After Targeted Therapy of Ceritinib (LDK378) for ALK-Rearranged Lung Adenocarcinoma Presenting With Hyperglycemia
por: Zheng, Jing, et al.
Publicado: (2017)

Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
por: Hu, Jing, et al.
Publicado: (2015)

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation
por: He, Wenxin, et al.
Publicado: (2022)

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9
por: Hida, Toyoaki, et al.
Publicado: (2018)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
por: Kitadai, Rui, et al.
Publicado: (2018)

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
por: Kiura, Katsuyuki, et al.
Publicado: (2018)

LDK378 improves micro- and macro-circulation via alleviating STING-mediated inflammatory injury in a Sepsis rat model induced by Cecal ligation and puncture
por: Ge, Weiwei, et al.
Publicado: (2019)

Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study
por: Kaneda, Hiroyasu, et al.
Publicado: (2020)

Efficacy and safety of ceritinib in anaplastic lymphoma kinase‐rearranged non‐small cell lung cancer: A systematic review and meta‐analysis
por: Tian, Wei, et al.
Publicado: (2020)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase
por: Ashinuma, Hironori, et al.
Publicado: (2018)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand‐1 inhibitor in anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Du, Ping, et al.
Publicado: (2020)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
por: Liao, Juanyan, et al.
Publicado: (2022)

Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report
por: Mai, Shixiong, et al.
Publicado: (2022)

Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
por: Kanaan, Zeyad, et al.
Publicado: (2015)

Correction to “Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report”
Publicado: (2023)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

ALK‐rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report
por: Xu, Yan, et al.
Publicado: (2018)

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
por: Tan, Daniel S.W., et al.
Publicado: (2020)

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
por: Li, Hui, et al.
Publicado: (2022)

ACT-01 THE SECOND GENERATION ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB EFFECTIVELY INDUCES CELL DEATH IN HUMAN GLIOBLASTOMA CELLS
por: Kawauchi, Daisuke, et al.
Publicado: (2019)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
por: Mansfield, A. S., et al.
Publicado: (2016)

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
por: Yue, Dongsheng, et al.
Publicado: (2021)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
por: Liu, Maobai, et al.
Publicado: (2019)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
por: Huang, Shih‐Hao, et al.
Publicado: (2019)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
por: Sasaki, Takaaki, et al.
Publicado: (2023)

Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
por: Katayama, Ryohei
Publicado: (2018)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g8to194afdpc7vlod0rbca5rmv